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Abstract
Background: Lymphatic metastasis is one of the leading causes of death in patients with different types of cancer
and is the main prognostic factor for the disease survival. The formation of new lymphatic vessels (lymphangiogenesis) in
primary tumors facilitates tumor cell dissemination to regional lymph nodes and correlates with distant metastases.
Lymphangiogenesis has thus emerged as a suitable therapeutic target to block metastases, but no anti-lymphangiogenic
compounds have been approved for clinical use to date. Therefore, new or improved therapies blocking lymphatic
metastases are urgently required.
Methods: We established murine breast tumors to assess the effect of AD0157 on tumor growth, lymphangiogenesis,
and lymphatic dissemination. Then, a battery of in vivo (mouse corneal neovascularization and ear sponges), ex vivo
(mouse lymphatic rings and rat mesentery explants), and in vitro (proliferation, tubulogenesis, wound-healing, Boyden
chambers, and spheroids) assays was used to give insight into the lymphangiogenic steps affected by AD0157. Finally, we
investigated the molecular pathways controlled by this drug.
Results: AD0157 was found to inhibit the growth of human breast cancer xenografts in mice, to strongly reduce
tumor-associated lymphangiogenesis and to block metastatic dissemination to both lymph nodes and distant organs.
The high anti-lymphangiogenic potency of AD0157 was further supported by its inhibitory activity at low micromolar
range in two in vivo pathological models and in two ex vivo assays. In addition, AD0157 inhibited lymphatic
endothelial cell proliferation, migration and invasion, cellular sprouting, and tube formation. Mechanistically, this
compound induced apoptosis in lymphatic endothelial cells and decreased VEGFR-3/-2, ERK1/2, and Akt
phosphorylations.
Conclusions: These findings demonstrate the suitability of AD0157 to suppress tumor-associated lymphangiogenesis.
Beyond discovering a new potent anti-lymphangiogenic drug that is worth considering in future clinical settings, our
study supports the interest of designing anti-lymphangiogenic therapies to avoid distant metastatic processes.
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Background
The elevated mortality rates seen in cancer patients are as-
sociated with the metastatic spread of tumor cells from
their initial origin sites to distant tissues [1]. Although
metastatic dissemination can occur via a variety of mecha-
nisms, most metastases arise following cell intravasation
into blood and/or lymphatic vasculature to further gain
access to the systemic circulation [2]. Indeed, clinicopatho-
logical studies in micrometastases, frequently in breast
cancers, suggest that lymphatic vessels are preferentially
used as the initial route for the tumor invasion rather than
blood vessels [3, 4]. This fact can be explained by the mor-
phological advantages and structural features of lymphatic
vessels that facilitate the intravasation and extravasation of
tumor cells and favor their survival in the lymphatic system,
giving advantages over the bloodstream [5]. Besides these
considerations, metastatic processes are usually supported
by a significant increase in the formation of new lymphatic
vessels, named lymphangiogenesis, in the primary tumors
and in the regional draining lymph nodes (LNs) [6].
In clinical practice, special attention is paid to the
regional LNs as the main players in the metastatic dissem-
ination [7]. Thus, LN status (presence or absence of tumor
cells) is used as a potential diagnostic marker for predicting
the pathologic stage of the disease, and it is essential for
therapeutic strategy decisions [8]. It has been reported that
tumor-draining LNs in cancer patients show enhanced
lymphangiogenesis even before of metastatic colonization
[9, 10]. LNs may serve as a permissive pre-metastatic
lymphvascular niche providing a supportive environment
for the survival and proliferation of metastatic cells and
promoting their further movement to distal organs [10].
Currently, breast cancer patients treated with hormonal or
anti-angiogenic therapies combined with other agents are
suffering from recurrence of secondary tumors in draining
LNs [11, 12]. Inhibition of angiogenesis results in hypoxic
condition in tumors that provokes the overexpression of
lymphangiogenic factors, enhancing tumor metastasis
through lymphatics [13, 14]. Therefore, targeting lymphan-
giogenesis represents a potential strategy to prevent or treat
lymphatic metastases. However, only few drugs designed
for the blocking of this crucial event are in clinical trials
nowadays (Tivantinib, Onartuzumab, Rilotumumab,
Trebananib, and IMC-3C5) [8, 15]. Most of these anti-
lymphangiogenic compounds are drugs targeting the
VEGF-C/VEGFR-3 signaling axis, the most relevant and
specific pathway that promotes lymphangiogenesis in
pathological situations [15].
In our continuous efforts to discover and characterize
new anti-angiogenic compounds, we previously screened
a plethora of natural compounds. AD0157, a pyrrolidine-
dione isolated from the fermentation broth of the marine
fungus Paraconiothyrium sp. HL-78-gCHSP3-B005, was
found to be the more potent anti-angiogenic drug [16].
On the basis of these findings, we sought to determine its
anti-tumor and, especially its anti-lymphangiogenic prop-
erties. Herein, we report for the first time that in the treat-
ment of human breast cancer xenografts in mice, AD0157
reduces tumor growth, blocks the invasion of tumor cells
to the draining LNs, and potently reduces metastases,
through a strong reduction of the lymphatic vasculature
in both primary tumors and in regional LNs. Evidences
supporting AD0157 as an anti-lymphagiogenic drug include
the inhibitory biologic effects of this compound in a wide
experimental battery of in vivo, ex vivo, and in vitro models.
AD0157 also induces apoptosis in lymphatic endothelial
cells (LECs) and mechanistically blocks VEGFR-3/-2
signaling pathways. Altogether, our results shed light on the
promising therapeutic potential of AD0157 as a new anti-




AD0157 compound (Additional file 1: Figure S1) obtained
from Biomar Institute S.A (León, Spain) was dissolved in
DMSO and stored in frozen aliquots until use. DMSO
was used in controls at the same percentage used in the
experimental conditions (up to 0.1%). For all assays, a pilot
study was first conducted to optimize the range of the
more effective AD0157 concentrations.
Animals
NOD/SCID mice, C57BL/6 mice, and Wistar rats were
purchased from Charles River (Saint-Germain-Nuelles,
France). Animal care and experimental procedures were
performed in strict compliance with the European
Communities Council Directive 2010/63/EU and the
Belgium legislation for the animal experimentation. All
experimental protocols were approved by the Local Ani-
mal Ethics Committee at the University of Liège (13/
1522), and the 3Rs principles were always implemented.
Cell culture and transfection
MDA-MB-231 breast adenocarcinoma cells were obtained
from the ATCC, and MDA-MB-231 cells expressing lucif-
erase (MDA-MB-231/Luc+) were generated by transfec-
tion with a plasmid containing the luciferase reporter
(Lipofectamine/Plus Reagent, Invitrogen). They were
grown in DMEM supplemented with glucose (4.5 g/L),
glutamine (2 mM), penicillin (50 IU/mL), streptomycin
(50 mg/L), amphotericin (1.25 mg/L), and 10% FBS, at
37 °C with 5% CO2 in air, until reaching 80% of con-
fluency. LECs used in this study were from adult human
dermal lymphatic microvasculature (hMVEC.dLy.Ad) and
were purchased from Lonza. LECs were cultured in
complete endothelial growth microvascular medium
(EGM-2 medium), composed of EBM-2 and single quotes,
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including 0.2% (v/v) hydrocortisone, 2% (v/v) hFGF-B,
0.5% (v/v) VEGF, 0.5% (v/v) R3-IGF-1, 0.5% (v/v) hEGF,
0.5% (v/v) ascorbic acid, 0.5% (v/v) Gentamicin/Ampho-
tericin-1000, and 5% (v/v) FBS, at 37 °C and humidified
5% CO2 atmosphere, until reaching 90–100% of con-
fluency. All experiments were carried out with LECs of
less than five passages.
Mice experiments for toxicology
NOD/SCID mice (n = 3) were daily treated for 30 days
with intraperitoneal injections of the maximal AD0157
dose (3 mg/kg) used in the in vivo tests. According to
the ethical protocol approved by the Local Animal Ethics
Committee, the appearance, behavior, body weight, mo-
tility, eating and drinking habits, skin turgor, and urine
output of mice were daily inspected to detect signs of
toxicity, pain, or distress. Moreover, after mice sacrifice,
the internal organs were inspected to ensure the absence
of inflammation, hemorrhage, or necrosis, among others.
Orthotopic mammary fat pad tumor growth in mice
MDA-MB-231/Luc+ cell suspensions (2 × 106 cells in 50:50
DPBS/Matrigel) were injected subcutaneously into the
fourth abdominal mammary glands of female NOD/SCID
mice. Tumor growth was assessed by measuring the length
and width of tumors every 3–4 days (tumor volume =
length ×width2 × 0.4) [17]. Mice bearing tumors with 50–
60 mm3 (day 20) were randomized into different groups
and treated daily with either vehicle (saline solution),
1.5 mg/kg or 3 mg/kg AD0157 drug. For in vivo imaging,
mice were intraperitoneally injected with 75 mg/kg D-lucif-
erin and the Lumina II IVIS instrument (Caliper Life Sci-
ences) was used for bioluminescence measurement
according to manufacturer’s recommendations. Animals
were sacrificed when tumor volume exceeded 600 mm3,
and tumors were harvested, weighed, and subjected to
immunohistochemistry or quantitative RT-PCR analyses.
Axillary LNs and the main mouse organs were excised, the
ex vivo bioluminescent signals were measured, and they
were preserved for immunohistological or quantitative
RT-PCR analyses.
Immunohistochemistry
Mammary tumors, LNs, and the main mouse organs were
harvested, fixed, dehydrated, embedded in paraffin and sec-
tioned in 5-μm slides. Then, samples were deparaffined, hy-
drated, and autoclaved for 11 min at 126 °C in Target
Retrieval Solution (Dako). Endogenous peroxidase activity
was quenched (3% H2O2 in PBS), and sections were
blocked. For lymphatic vasculature detection, a primary
polyclonal LYVE-1 antibody was used (1/100, R&D Sys-
tems) and samples were revealed with the Phenol Red
chromogen kit (Dako). To detect MDA-MB-231/Luc+ cells,
a mouse monoclonal anti-human-ki-67 antibody (1/100,
clone MIB-1, M7240, Dako) was applied and the signal was
developed by treatment with 3,3’-diaminobenzidine (DAB,
Dako). Finally, samples were counterstained with
hematoxylin/eosin, washed, dehydrated, mounted, and
visualized.
Quantitation of gene expression
RNA was extracted from mammary tumors, LNs, and
LECs using the RNeasy Mini kit (Qiagen). Tumors and
LNs were previously frozen and pulverized with MagNA
Lyser (Roche), and reverse transcription was conducted
on 1 μg of total RNA (First Strand cDNA Synthesis Kit,
Roche) followed by real-time PCR (FastStart SYBR
Green Master, Roche) with the following specific primers
(Eurogentec): sense, 5′- TCCTGGTATGACAATGAATA
CGG-3′, and antisense, 5′- TCTCTTGCTCAGTG
TCCTTGCT-3′, for GADPH; sense, 5′-CCTCGTGCAA
GACCTTTCCATT-3′, and antisense, 5′-CCCACAC
CTGGGGTTTGAGAAA-3′, for LYVE-1; sense, 5′-
CCCACGCAGACATCAAGACG-3′, and antisense, 5′-
TGCAGAACTCCACGATCAGC-5′, for VEGFR-3; and
sense, 5′-TTCCACGTGACCAGGGGTCCT-3′, and
antisense, 5′-AGCTGCCTGACCACGCAATGT-3′, for
VEGFR-2. Quantification was performed by normaliza-
tion of the values obtained for the endogenous GADPH
rRNA amplification.
In vivo lymphangiogenesis assays
Mouse corneal neovascularization assay
Inflammatory corneal neovascularization was induced by
thermal cauterization (Optemp II V; Alcon Surgical) in the
central cornea of anesthetized C57BL6 mice [18]. Next, in-
traperitoneal injections with vehicle (saline solution) or
AD0157 (1.5 or 3 mg/kg) were daily administered during
8 days. At mice sacrifice, corneas were dissected, fixed,
blocked, and double immunostained for lymphatic and
blood vessel detection, as detailed previously [18].
Lymphatic and blood vasculatures were quantified with the
toolbox of MATLAB 8.3 (R2014a) software, and the follow-
ing parameters were analyzed: area, branching (number of
bifurcations), end-point (number of sprout tips) and length
densities, and the number and length of filopodias [19].
Mouse ear sponge assay
Sterile compressed gelatin sponges (Gelfoam, Pfizer) were
cut in small cylindrical fragments (~3 mm3) and incubated
with serum-free DMEM containing recombinant human
(rh) VEGF-C (1 μg/mL; R&D Systems) and with or with-
out AD0157. Then, they were soaked with interstitial type
I collagen gel and implanted into the mouse ears. Every
2 days, serum-free DMEM containing AD0157 or not
(controls) were injected in the apex of the ear, and after
3 weeks, the ears were excised and frozen in tissue optimal
cutting temperature (OCT) compound (VWR Chemical).
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Blocks were sectioned, processed for lymphatic and blood
vessel immunodetection, scanned, and automatically
quantified, as previously described [20].
Ex vivo lymphangiogenesis approaches
Three-dimensional mouse lymphatic ring explants
The lymphatic sprouting from explants was analyzed
using ex vivo mouse 3D-lymphatic ring cultures [21].
Briefly, thoracic ducts dissected from C57BL6 mice were
cut into 1-mm pieces and embedded in rat tail intersti-
tial type I collagen gel. Explants were cultured in
MCDB131 (Invitrogen) supplemented with 2% Ultroser
G (Pall Life Sciences), in the presence or absence of
AD0157, at 37 °C in 5% O2, 5% CO2, and 90% N2 for
7 days. Cultures were photographed, and computerized
quantifications were performed on binary images. A grid
of concentric rings was generated by successive incre-
ments at fixed intervals of thoracic duct boundary, and
the number of microvessel-grid intersections (Ni) was
counted [21].
Rat mesentery cultures
Mesenteric windows, the translucent and thin connective
tissue between artery/vein pairs in the small intestine, were
surgically dissected from adult Wistar rats (Charles River),
as described [22]. Explants were cultured in serum-free
MEM supplemented with rhVEGF-C (200 ng/mL), with or
without AD0157 for 5 days. Whole mounted explants were
washed, fixed, permeabilized, and immunolabeled with an
anti-VEGFR-3 primary antibody (1/50; Santa Cruz
Biotechnology) and an Alexa Fluor 488-conjugated second-
ary antibody (1/200; Invitrogen). Rat mesenteric windows
were visualized, and computerized analyses were performed
to analyze the lymphangiogenic response.
In vitro lymphangiogenesis tests
Cell proliferation assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide or MTT dye reduction assay in 96-well micro-
plates was used [20]. Briefly, LECs (3 × 103 cells/well) and
MDA-MB-231/Luc+ cells (2 × 103 cells/well) were
incubated with serial dilutions of AD0157 for 3 days, and
then, MTT (5 mg/mL in PBS) was added. IC50 values were
calculated as those concentrations of AD0157 yielding 50%
cell survival, taking the values obtained for control as 100%.
Tubulogenesis assay
LECs (5 × 105 cells/well) were embedded in a collagen
matrix containing or not AD0157 and cultured in 2% FBS
supplemented EGM-2 medium, with or without the drug.
The formation of capillary-like structures was monitored
in the next 24 h, and pictures were quantified with the
image analysis toolbox of MATLAB 8.3 (R2014a) software
(Mathworks, Inc).
Migration and invasion assays
The migratory activity was assessed using the scratch
assay. Cells in a confluent monolayer were scratched and
supplied with complete medium containing 2% FBS, in
the absence or presence of AD0157. Wounded areas were
photographed at 0 and 48 h of incubation. Mitomycin C
(0.1 μg/ml; Sigma-Aldrich) was added to inhibit cellular
proliferation. The percentage of recovered area was deter-
mined by image analysis (NIH Image 1.6 software). For
invasion assays, LECs (1.5 × 105) in EBM-2 medium
containing 0.5% FBS, with or without AD0157, were
seeded in the upper compartment of Transwell inserts
(Corning) coated with 0.2% gelatin. The lower compart-
ment was filled with EBM-2 containing 1% FBS and
rhVEGF-C (400 ng/ml; R&D Systems). After 48 h, cells
were fixed, stained with Giemsa solution (Millipore), and
filters were visualized and quantified.
Spheroid assay
LEC spheroids were generated as previously described
[23], embedded in collagen gels with or without AD0157
and cultured in 2% FBS supplemented EGM-2 medium
for 24 h. Then, spheroids were examined and pictures
were analyzed using a computer-assisted method of
quantification [24]. The convex envelope area (minimal
convex polygon area containing the spheroid core and
all sprouting cells), the migrated LEC area (area contain-
ing migrating cells), and the LEC density (number of
pixels belonging to cells that intersect the circle “i”, Ni,
normalized by the corresponding perimeter Pi) with the
maximal length (Lmax) were analyzed.
Apoptosis and cell cycle analyses
Cells were treated or not with AD0157 during 14 h, and
apoptosis was evaluated by Hoechst 33258 staining, flow
cytometry, and caspase-3-7 activity. For Hoechst staining,
cells were fixed, stained with Hoechst 33258 (1 μg/mL,
Sigma-Aldrich), and observed under a fluorescence micro-
scope (Leica, TCS-NT). For cell cycle analysis, cells were
fixed, stained with propidium iodide solution (40 μg/mL
propidium iodide and 0.1 mg/mL RNase-A; Sigma-Aldrich)
and percentages of subG1, G1, and S/G2/M populations
were determined using a MoFlo Dakocytomation cytometer
(Dako, Denmark). For the determination of caspase-3/-7
activity, the Caspase-Glo® 3/7 reagent, provided in the
ApoTox-GloTM Triplex Assay Kit (Promega), was used ac-
cording to manufacturer’s instructions.
Immunoblotting
Serum-starved subconfluent LEC cultures were incubated
in the presence or absence of AD0157 for 2 h and then
challenged for 30 additional minutes with rhVEGF-C
(400 ng/mL), rhVEGF-C156S (500 ng/mL; R&D Systems),
or rhVEGF-A (100 ng/mL; R&D Systems). Cell lysates
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were analyzed by SDS-PAGE, electrotransferred to
nitrocellulose membranes (GE Healthcare Life Sciences),
and blots were probed with primary antibodies against
pVEGFR-3 (1/1000; Cell Application), VEGFR-3 (1/1000;
Millipore), pVEGFR-2, VEGFR-2, pERK1/2, ERK1/2, pAkt,
Akt, (1/1000; Cell Signaling), and GADPH (1/2000;
Millipore). Detection was carried out with chemilumines-
cence system ECL Western Blotting Substrate (Pierce), and
bands were quantified and expressed as phosphorylated
protein/total protein ratio.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5.0 software (San Diego, CA, USA). For the tumor growth
and metastasis incidence, one-way ANOVA and chi-
square tests were applied, respectively. Otherwise, results
were analyzed using the non-parametric Mann-Whitney
test; p < 0.05 was considered significant. All data are
expressed as means ± s.e.m. (standard error of the mean).
Results
AD0157 inhibits tumor growth and tumor-associated
lymphangiogenesis in orthotopic mammary xenografts
Human breast adenocarcinoma MDA-MB-231/Luc+ cells
were injected into the fourth mammary glands of NOD/
SCID mice, and tumor growth was continuously moni-
tored. In mice administrated with the higher AD0157 dose
(3 mg/kg), tumor growth was drastically blocked after
10 days of the first drug injection, with the maintenance
of this inhibitory pattern until the end of the experiment
(Fig. 1a). AD0157 did not exhibit any toxicity assessed by
mice body weight measurements (Fig. 1b), visual examina-
tions, and inspection of the internal organs at sacrifice.
IVIS imaging and bioluminescence quantifications at the
end of the experiment revealed smaller tumor sizes in
AD0157-treated mice. Furthermore, the tumor-inhibitory
effect of AD0157 was more potent in those mice injected
with 3 mg/kg than in the group injected with 1.5 mg/kg
(Fig. 1c, d). Tumor weight of harvested mammary tumors
(Fig. 1e) and macroscopic photographs (Fig. 1f) further
confirmed that AD0157 significantly decreased the MDA-
MB-231/Luc+ xenograft growth.
To examine tumor cell proliferation and tumor-
associated lymphangiogenesis in primary tumors, im-
munohistochemical analyses were performed. Treat-
ments with AD0157 decreased the density of human
proliferating cells (Ki-67+ cells) and the density of
lymphatic vasculature in tumors (Fig. 1g). A 1.7 and
2.4-fold decrease in Ki-67+ cell density was seen in
mice treated with 1.5 and 3 mg/kg AD0157, respect-
ively (0.36 ± 0.017 versus 0.25 ± 0.021, p < 0.05; 0.36 ±
0.017 versus 0.15 ± 0.018, p < 0.001). Importantly, a
potent anti-lymphangiogenic effect of this compound
was shown by the huge reduction of the lymphatic
density upon treatment: 2.2 and 9-fold reduction with
1.5 and 3 mg/kg AD0157, respectively (0.09 ± 0.008
versus 0.04 ± 0.006, p < 0.001; 0.09 ± 0.008 versus 0.01
± 0.002, p < 0.001) (Fig. 1h). These data were con-
firmed by analyzing the messenger RNA (mRNA)
expression of LYVE-1 in complete mammary tumors
extracts (Additional file 2: Figure S2).
AD0157 reduces tumor colonization and lymphatic
density in draining LNs
Tumor-draining LNs from MDA-MB-231/Luc+ tumor-
bearing mice were resected after mice sacrifice. Control
groups frequently developed tumor-draining LN metas-
tases, with 100% of LNs positive for bioluminescent
signal (presence of tumor cells) (Fig. 2a). In contrast,
only 65 and 30% of the analyzed LNs showed positivity
for the presence of human breast cancer cells, in mice
daily treated with 1.5 and 3 mg/kg AD0157, respectively
(Fig. 2a). In addition, LNs harvested from AD0157-treated
mice were smaller than those belonging to control ones
(Fig. 2a). Quantification of the ex vivo bioluminescent sig-
nals through Xenogen acquisitions revealed a significant
decrease in the averaged bioluminescence of tumor-
draining LNs from AD0157-treated mice (Fig. 2b). These
data were confirmed by a clear reduction in the Ki-67+ cell
density in LNs (Fig. 2c, d). Interestingly, the maximal
distance (Lmax) reached by tumor cells inside the LNs
(distance measured from the LN edge) was drastically
decreased (Fig. 2d). In addition, tumor-draining LNs
harvested from control mice displayed enlarged lymphatic
vessels, and they were distributed throughout the paracor-
tex and medullar area, reaching values of 0.1 ± 0.007 for
the lymphatic density and 0.47 for the Lmax (Fig. 2c, d).
In sharp contrast, LNs from mice injected with 3 mg/kg
AD0157 showed a lower lymphatic density (0.048 ± 0.01)
together with a diminished Lmax (0.31), being the
lymphatic vasculature mostly located in the paracortical
region (Fig. 2c, d). LYVE-1 mRNA expression in complete
LNs validated the previous results (Additional file 2:
Figure S2). These data clearly indicate that AD0157 blocks
LN colonization as well as lymphatic vasculature remodel-
ing in draining LNs.
AD0157 potently prevents metastases in distant organs
To determine whether AD0157 could prevent tumor
cell invasion and distant metastases, the main organs
(brain, lungs, intestines, kidneys, spleen, and uterus)
were resected at mice sacrifice and examined with
the IVIS imaging system. The organs from mice
injected with the saline solution (drug vehicle) ex-
hibited higher bioluminescent signals compared to
those organs resected from mice treated with
AD0157, indicating an anti-metastatic effect of this
drug (Fig. 3a). Immunostainings for human Ki-67
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confirmed the presence of infiltrating tumor cells in
the different organs (Fig. 3b). AD0157 treatment (1.5
and 3 mg/kg) prevented the development of distant
metastases (Fig. 3c). Interestingly, only the liver in
one mouse (8.3%) and the lungs in two mice (16.7%)
showed tumor cells in mice treated with 3 mg/kg
AD0157, and no metastatic dissemination was found







Fig. 1 AD0157 reduces tumor growth and lymphangiogenesis in orthotopic mammary xenografts. a Evolution of tumor volumes in NOD/SCID
mice implanted with MDA-MB-231/Luc+ cells and treated daily with vehicle (saline solution) or AD0157 (1.5 or 3 mg/kg) for 25 days, as indicated
on top of the graph. Dashed line indicates the tumor volume (50 mm3) reached by tumors before drug treatment. Crosswise lines indicate the
starting point for the statistical differences shown at right. b Mouse body weights before and during treatments. ns denotes no statistical
differences between groups. c Representative in vivo bioluminescent signals of mice at the end of the treatment. d Quantification of tumor
bioluminescent radiance. e Tumor weights at the end of the experiment. f Representative pictures of tumors harvested from mice treated with
vehicle (control) or AD0157 (1.5 and 3 mg/kg). Each square represents a surface of 2.25 cm2. g Representative histological sections showing
human ki-67 (proliferation marker, in brown) and LYVE-1 (lymphatic vessel marker, in dark pink) stainings in mammary tumors. Scale bars represent
100 μm. h Quantification of human ki-67+ cell and lymphatic densities in histological sections of mammary tumors. Data are presented as
mean ± s.e.m. One-way ANOVA significance test, followed by the Bonferroni test, was used to compare the tumor growth in the different
conditions. The Wilcoxon-Mann-Whitney was applied for the rest of statistical tests. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 12 mice/group)
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To determine whether tumor cells and LECs were
equally sensitive to this drug, MDA-MB-231/Luc+
cells and LECs were subjected in vitro to different
AD0157 concentrations for IC50 value calculations.
LEC proliferation was suppressed with at least 5-
fold lower dose than MDA-MB-231/Luc+ one (IC50
= 2.5 μM for LECs and IC50 = 13.8 μM for
MDA-MB-231/Luc+) (Additional file 3: Figure S3).
These data suggested that LECs were the most
susceptible to AD0157 and prompted us to apply the






Fig. 2 AD0157 reduces tumor colonization and lymphatic density in draining LNs. a Representative pictures of ex vivo bioluminescent signals
recorded in draining LNs at mice sacrifice. The percentage of positive LNs for tumor cells is indicated. b Quantification of bioluminescent radiance in
LNs. c Immunostainings of human Ki-67 (proliferative cells in brown, left panels) and LYVE-1 (lymphatic vessels in dark pink, right panels) in whole LN
histological sections. Panels at high magnification illustrate the region delineated by the square in the complete LNs. Scale bars represent 250 μm. d
Human ki-67+ cell density (surface occupied by tumor cells divided by the total LN surface), lymphatic density (surface occupied by lymphatic vessels
divided by the total LN surface), and spatial distributions of tumor cells and lymphatic vessels in LNs. The spatial distribution is calculated from the LN
edge, where the distance is equal to 0
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AD0157 impairs pathological lymphangiogenesis in vivo
and interferes with the lymphangiogenic process ex vivo
We further explored the efficacy of AD0157 in inhibiting
lymphangiogenesis in vivo and ex vivo. In an inflamma-
tory mouse corneal model, although at day 9 post-injury,
lymphatic vasculature was evident in mice treated with
the vehicle, AD0157-treated mice exhibited a reduced
lymphatic vascular network (Fig. 4a). Computerized
quantifications revealed a decrease in the length and end-
point lymphatic densities in corneas of mice treated with
1.5 and 3 mg/kg AD0157. Furthermore, the lymphatic
area and branching densities were diminished in corneas
of mice administered with the highest AD0157 dose
(3 mg/kg/day) (Fig. 4b). The spatial distribution curve of
lymphatic vessels around the limbus revealed impaired




Fig. 3 AD0157 prevents distant metastases. a Representative ex vivo bioluminescent signals of distant organs (brain, lungs, liver, intestines, kidneys, spleen,
and uterus). b Immunohistochemical images visualizing micrometastases by human Ki-67 detection (in brown). Scale bars represent 250 μm. c Number
and percentage of organs colonized by metastatic cells. Data are presented as mean ± s.e.m., and the Wilcoxon-Mann-Whitney significance tests were used
to compare the differences between vehicle (control) and AD0157 treatment. Chi-square with Yates’ correction test was used to analyze the metastasis
incidence. *p< 0.05, **p< 0.01, ***p< 0.001 (n= 12 mice/group)
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treated mice (Fig. 4b). We next analyzed the migrating
cells at the tip of the lymphatic buds, characterized by nu-
merous cytoplasmic extensions or filopodias. A decrease
in the number and length of filopodia-like extensions was
found in corneas of treated mice (Fig. 4a, b). On the other
hand, the ear sponge assay revealed that sponges soaked
with rhVEGF-C and AD0157 at different concentrations
displayed decreased lymphatic vessel density (Fig. 5a, b).
Importantly, the highest dose of AD0157 (2.5 nmol) dras-
tically suppressed the lymphangiogenic response with a 5-
a
b
Fig. 4 AD0157 impairs corneal neovascularization in mice. a Representative flat-mounted cauterized corneas harvested from control and AD0157-treated
mice at day 9 post-injury. Lymphatic (LYVE-1 positive) and blood (CD31 positive) vessels appear in green and in red, respectively, at low (left panels) and high
(middle panels) magnifications. Scale bars represent 1000 and 500 μm, respectively. Panels at right correspond to representative pictures of filopodia-like
structures (white arrowheads) displayed by migrating LECs. Scale bars represent 10 μm. b Computerized measurements of different parameters: lymphatic
area density (area covered by neoformed lymphatic vessels), length density (cumulative length of vessels), branching density (number of bifurcations), end--
point density (number of sprout tips), spatial lymphatic distribution (a grid was applied on each cornea picture to establish the distribution curves of capil-
laries around the limbal vessels; Ni corresponds to the number of vessel intersections with the grid versus the distance to the limbus), number and length
of filopodia-like structures in a total length of 25 μm at the end of the lymphatic vessel, and blood area density (area covered by neoformed blood vessels).
Results were divided by the total cornea area to obtain densities. Values are expressed as mean ± s.e.m., and the Wilcoxon-Mann-Whitney significance tests
were used to compare the differences between control and AD0157 treatments.*p< 0.05, **p< 0.01, ***p< 0.001 (n= 12 mice/group)




Fig. 5 AD0157 inhibits in vivo VEGF-C-induced lymphangiogenesis and blocks the lymphangiogenic process ex vivo. a Representative pictures of gelatin
sponges soaked with either rhVEGF-C (1 μg/mL) alone (positive control) or rhVEGF-C + AD0157 at different concentrations and implanted between the
mouse ear skin layers. Lymphatic and blood vasculatures were examined by LYVE-1 (green) and CD31 (red) immunostainings, respectively. Dapi staining
was used to detect cell nuclei (blue). Scale bars represent 1500 and 500 μm on higher magnification. A total of 10 mice were analyzed in each experimental
condition. b The graphs represent the computerized quantification of the lymphatic density (left panel), the normalized frequency of lymphatic vessels from
the sponge edge to its center (middle panel), and the blood density (right panel). Arrows indicate the maximal distance of LEC migration (Lmax). c Ex vivo
lymphatic sprouting from mouse thoracic duct explants embedded in a type I collagen gel and cultured in the absence (control) or presence of AD0157
for 7 days. Scale bars represent 500 μm. d Graphs represent the number of microvessel intersections (Ni) quantified on binarized images using a grid of
concentric rings (left graph) and the LEC density at a distance (d) = 0.25 mm from the ring border (right graph). A total of 10 lymphatic rings collected from
five different mice were analyzed in each experimental condition. e Microvessel outgrowth in rat mesenteric windows incubated in medium containing
either rhVEGF-C (200 ng/mL) alone or in combination with AD0157, ranging from 0.5 to 2.5 μM, for 5 days. Scale bars represent 200 μm. f Lymphatic
density and number of branchings in rat mesenteric windows exposed or not to AD0157. A total of 10 mesenteric windows harvested from five different
rats were evaluated in each experimental condition. Values are expressed as mean ± s.e.m., and the Wilcoxon-Mann-Whitney significance tests were used
to compare the differences between control and AD0157 treatment. *p< 0.05, **p< 0.01, ***p< 0.001
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fold reduction compared with untreated and rhVEGF-C-
stimulated sponges (Fig. 5b). Furthermore, in this
experimental condition most lymphatic vessels remained
located close to the sponge border, with a maximal
distance of lymphatic vessel penetration (Lmax) of
1.3 mm, while in rhVEGF-C-stimulated sponges lymphatic
vessels reached a distance superior of 1.7 mm (Fig. 5b).
As the two above-described lymphangiogenesis models
are also suitable for investigating angiogenesis, the impact
of the studied drug on the blood network was evaluated in
corneas and mouse ear sponges. As expected, the highest
concentration of AD0157 (3 mg/kg) induced a reduction in
blood vessel formation (Figs. 4 and 5a, b). These data are in
line with our previous work about the anti-angiogenic
properties of AD0157 [16]. Interestingly, AD0157 was more
potent on lymphangiogenesis than on angiogenesis, and
doses able to interfere with the lymphangiogenic process
were not potent enough to block the angiogenic one
(Figs. 4b and 5b).
Ex vivo cell sprouting and outgrowing of new lymph-
atic endothelial capillaries was evaluated in lymphatic
rings [21] cultured with or without different doses of
AD0157. While control explants exhibited an important
lymphatic outgrowth at day 7, AD0157 decreased the
number of microvessels and fully blocked LEC sprouting
upon 2.5 μM (Fig. 5c, d). To further validate these re-
sults, the drug was added to rat mesenteric windows in-
cubated in the presence of rhVEGF-C (200 ng/mL).
AD0157 at 2.5 μM reduced to half the lymphatic vessel
density and the number of branchings (Fig. 5e, f ).
AD0157 blocks tube formation, migration, invasion, and
sprouting of LECs in vitro
To investigate how AD0157 affects the lymphangiogenic
process, a battery of in vitro assays was used. Again, a
dose-dependent effect of AD0157 was observed in all
the models, with a drastic blockade in the studied LEC
property when the drug was used at 1 μM. Thus, the
compound impaired the organization of LECs in a
3D-network of tubes with a reduction in the tube area
density and the number of branchings (Fig. 6a, b). In the
wound-healing assay (Fig. 6c, d) and in Boyden
chambers (Fig. 6e, f ), AD0157 inhibited the migra-
tion and invasion of LECs. Moreover, AD0157 treat-
ment blocked vessel sprouting in the LEC spheroid
model, which mimic the 3D environment in which
LECs proliferate, migrate, and form new tubes
(Fig. 6g). A huge reduction of LEC sprouting and
migration was achieved at AD0157 1 μM as assessed
by the different parameters measured: (i) the convex
envelop area; (ii) the area occupied by migrated cells;
(iii) the spatial distribution of sprouting cells around
the spheroid core, and, finally, (iv) the cell density at
a distance of 0.13 mm of the spheroid center
(Fig. 6h). Surprisingly, doses of AD0157 up to
10 μM were needed to interfere with MDA-MB-231/
Luc+ cell migration in the scratch assay (Additional
file 4: Figure S4a, b).
AD0157 induces LEC apoptosis
Firstly, chromatin morphology was analyzed in treated
and untreated cells stained with Hoechst 33258
(Fig. 7a). AD0157 provoked chromatin condensation
at 0.5 and 1 μM in 21.3 and 29.5% of cells, respect-
ively (Fig. 7b). To confirm this finding, cell cycle ana-
lyses by flow cytometry were performed in LECs
stained with propidium iodide. In Fig. 7c are dis-
played representative flow cytometry diagrams show-
ing increased apoptotic subG1 cell subpopulation
upon AD0157 treatment. AD0157 used at 0.5 and
1 μM led to a 5- to 6-fold enhancement of apoptotic
cells (Fig. 7d). It is worth mentioning that differences
were detected not only in the subG1 but also in the
S/G2/M subpopulations (Fig. 7d). Moreover, the “ef-
fector” caspase-3/-7 activity, which plays a crucial role
in the apoptosis induction, was activated upon
AD0157 treatment (0.5 and 1 μM) (Fig. 7e).
Importantly, AD0157 was more potent to induce LEC
apoptosis than MDA-MB-231/Luc+ cell apoptosis,
and higher drug concentrations were required to
obtain similar effects in breast cancer cells
(Additional file 4: Figure S4c-e).
AD0157 interferes with the activation of VEGFR-3,
VEGFR-2, and downstream mediators
Since VEGFR-2, and especially VEGFR-3, are expressed
in LECs and involved in lymphangiogenesis, we first in-
vestigated whether AD0157 could modulate the expres-
sion levels of both receptors. However, VEGFR-3 and
VEGFR-2 mRNA levels were similar in the absence or
presence of this compound (Fig. 8a). It is also well
known that activation of VEGFR-3/2 heterodimers and/
or VEGFR-3 homodimers through phosphorylation
mainly triggers the lymphangiogenic response [25].
Herein, LECs were stimulated with different growth fac-
tors (rhVEGF-C, rhVEGF-C156S, or rhVEGF-A).
Stimulation with rhVEGF-C resulted in VEGFR-3 activa-
tion, as well as stimulation with rhVEGF-A led to a
VEGFR-2 induction (Fig. 8b). Downstream actors such
as ERK1/2 and Akt were also activated after growth fac-
tor addition (Fig. 8b). Interestingly, a pretreatment with
AD0157 at 0.5 and 1 μM decreased VEGFR-3, VEGFR-2,
ERK1/2, and Akt phosphorylation levels (Fig. 8b, c).
Similarly, VEGFR-3, ERK, and Akt activations were ob-
tained after stimulation with rhVEGF-C156S, a mutant
rhVEGF-C form, which binds VEGFR-3, but not
VEGFR-2. In this experimental situation, only the higher
AD0157 dose (1 μM) was able to inhibit VEGFR-3 and
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downstream mediator phosphorylations (Fig. 8b, c). There-
fore, AD0157 exerts, at least in part, its inhibitory function
through an interference with the VEGFR-3 and VEGFR-2
signaling pathway activations.
Discussion
In this work, we are assigning unprecedented and very
potent anti-lymphangiogenic and anti-local and distant








Fig. 6 AD0157 suppresses lymphangiogenesis in vitro by interfering with LEC tubulogenesis, migration, invasion, and sprouting. a Tube-like structures
formed by LECs in a collagen matrix, in the absence (control) or presence of different AD0157 concentrations. Scale bars represent 200 μm. b Computerized
quantification of the tube area density and the number of branchings (common point between 2 or more tubes). c Pictures showing the area recovered
by LECs after 48 h of wounded LEC monolayers, in the absence or presence of different AD0157 doses. Dashed lines in pictures indicate the initial (time 0)
wound edges. Scale bars represent 100 μm. d Percentage of the initial cell-free area recovered by endothelial cells. e Representative images of the invaded
LECs across a Transwell chamber coated with 0.2% gelatin, after 48 h of treatment. f Percentage of invaded cells. g LEC sprouting from spheroids
embedded in a collagen-methyl cellulose gel under different experimental conditions. Scale bars represent 100 μm. h Computerized quantifications of the
convex envelope area (minimal convex polygon area containing the spheroid core and all sprouting cells), the migrated cell area (area containing
migrating cells), the LEC density (number of pixels belonging to cells that intersect the circle “i”, Ni, normalized by the corresponding perimeter) at different
distances from the spheroid core and values of the LEC density at the specific distance of 0.13 mm from the spheroid centre, in control and
AD0157-treated spheroids. Arrows indicate the maximal length (Lmax). Values are expressed as mean ± s.e.m., and the Wilcoxon-Mann-Whitney significance
tests were used to compare the differences between control and AD0157 treatment. *p< 0.05, **p< 0.01, ***p< 0.001 (n= 5 independent tests)
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For the preclinical characterization of AD0157 as a
powerful lymphangiogenic inhibitor, a panel of 3 in vivo,
2 ex vivo, and 7 in vitro models has been applied. We
have first used the mammary fat pad xenograft model,
which recapitulates human breast cancer growth and
metastatic dissemination to regional LNs and distant or-
gans, including the brain, lungs, and liver, as observed in
patients. MDA-MB-231/Luc+ breast cancer cells used in
this approach highly express VEGF-C, the main lym-





Fig. 7 AD0157 induces apoptosis in LECs. Analysis of apoptosis in LECs treated or not with AD0157 for 14 h. a Chromatin condensation revealed
by Hoechst 33258 staining. Scale bars represent 100 μm. b Percentages of cells with condensed chromatin (total cells were counted by using
bright field). c Cell cycle distribution in LECs stained with propidium iodide and analyzed by flow cytometry. d Percentages of subG1 (apoptotic
cells with invariable DNA content), G1 (cells in interphase before cell division), and S/G2/M (DNA replication and mitosis) LEC subpopulations. e
LEC Caspase-3/-7 activity. Values are expressed as mean ± s.e.m., and the Wilcoxon-Mann-Whitney significance tests were used to compare the
differences between control and AD0157 treatment. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 5 independent tests)
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leading to tumor-associated lymphangiogenesis [26–29].
Our results demonstrate that mammary tumors mark-
edly regressed under AD0157 treatment and lymphatic
vessel formation was inhibited in these primary tumors.
Importantly, the impaired lymphatic vessel formation in-
duced by AD0157 within primary tumors was associated
with reduced metastasis in draining LNs. Moreover,
given that the incidence of the organ metastasis was also
reduced by AD0157 treatment, restricting metastasis to
regional LNs by AD0157 could be useful to suppress sys-
temic dissemination of breast cancer cells.
Next, to determine the respective properties of AD0157
on LECs and cancer cells, we investigated in vitro the ef-




Fig. 8 AD0157 blocks VEGFR-3 and VEGFR-2 signaling cascades in LECs. a Values of VEGFR-3 and VEGFR-2 mRNA expression levels in LECs incubated with
different AD0157 concentrations. b Representative Western-blots showing the effect of AD0157 on VEGFR-3, VEGFR-2, ERK1/2, and Akt phosphorylations
after stimulation with rhVEGF-C (400 ng/mL), rhVEGF-C156S (500 ng/mL), or rhVEGF-A (100 ng/m). c Quantification by densitometry of Western blots.
Results are expressed as the percentage of phosphorylated proteins/total protein ± s.e.m. of five Western blots. The Mann-Whitney-Wilcoxon test was used
to determine if the differences among control (stimulated LECs without AD0157 treatment) and AD0157-treated and stimulated LECs were statistically
significant. *p< 0.05, **p< 0.01, ***p< 0.001 versus control
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proliferation. Interestingly, LECs showed a substantially
lower IC50 value than MDA-MB-231/Luc+ cells with this
agent. Moreover, this value was also lower than those
already described for other endothelial cells and tumor
cells [16], revealing that LECs were the most sensitive cells
to the studied drug. In line with the above consideration,
it is worth noting that AD0157 blocked MDA-MB-231/
Luc+ migration at 5 μM but not at the lower doses
(≤1 μM) used for LECs. This assumption was further sup-
ported by the higher doses needed to induce apoptosis on
MDA-MB-231/Luc+ cells, compared with the apoptotic
induction achieved by AD0157 on LECs. Moreover, the
IC50 value for LECs was lower than that observed in other
endothelial cells [16]. All these findings provided an
evidence-based reason for the rational in-depth
characterization of AD0157 in different in vivo, ex vivo,
and in vitro lymphangiogenesis models. In all models
used, a dose-response inhibition was observed in the
lymphatic growth, migration, sprouting, and tubulogen-
esis. Therefore, the compound is able to interfere with the
different main steps of the lymphangiogenic process.
Besides its anti-lymphangiogenic properties, the apoptosis
induction by AD0157 can be considered as an additional
ability supporting the mechanism of lymphangiogenesis
suppression and may contribute to the effectiveness of the
drug. Collectively, these data emphasize the powerful
anti-lymphangiogenic activity of AD0157, which is rein-
forced in vivo by the effect, although less efficient, exerted
on tumor cells. They underline the multifactorial feature
of this natural compound without any obvious systemic
toxic effects.
From a mechanistic standpoint, we demonstrated that
AD0157 is a dual inhibitor. Treatment with this drug
abrogated the activation of VEGFR-2, and especially of
VEGFR-3, induced by rhVEGF-A and rhVEGF-C or
VEGF-C156S, respectively. VEGFR-3 plays a pivotal role in
the lymphatic vascular formation, and VEGFR-3 inhibition
has been shown to disrupt the cellular functions of LECs
and adult lymphangiogenesis [5]. On the other hand,
VEGFR-2 could be involved in lymphangiogenesis through
its indirect effect on LECs by forming heterodimers with
VEGFR-3 [5]. Moreover, phosphorylations of downstream
molecules such as ERK and Akt were suppressed upon
AD0157 treatment as well. Given the recognized crucial
roles played by ERK- and Akt-dependent signaling cascades
in the development of many tumors types and resistance to
chemotherapy [30, 31], this AD0157 property should be
taken into account for further therapeutic evaluations.
Targeting VEGF and VEGFR signaling in a tumor has
been considered as a promising and attractive therapeutic
strategy, and several approaches have been investigated,
including the use of antibodies against VEGF receptors
[32, 33], small tyrosine kinase inhibitors [34–36], and sol-
uble receptors that trap lymph/angiogenic factors [37].
For instance, targeting the VEGF pathway in gastric can-
cers has gained increasing attention after the results ob-
tained in phase III clinical trials, which demonstrate
superior survival outcome with some anti-angiogenic
drugs, such as ramucirumab, apatinib, and bevacizumab,
than with the standard therapy [38]. Nevertheless, further
studies are required to deeply explore the timing and
potentially predictive biomarkers of angiogenesis inhibi-
tors to improve the selection of patients and improve
clinical benefit. Other tyrosine kinase inhibitors are
displaying interesting properties in the clinic. Anlotinib, a
broad-spectrum anti-tumor drug designed to primarily
inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret,
has shown manageable toxicity, long circulation, and an-
ti-tumor potential in patients with advanced refractory
solid tumors in phase I clinical trials [39].
Given the complexity and redundancy of the VEGF sig-
naling network in promoting angiogenesis and lymphan-
giogenesis, multitargeting by small molecules may be an
appropriate strategy for effective inhibition of tumor-
associated lymphangiogenesis. The suppression of either
VEGFR-3 or VEGFR-2 alone might not be sufficient to
inhibit cellular signaling and the whole lymphatic process.
AD0157 has been reported as an anti-angiogenic drug in
different models: the chicken chorioallantoic membrane
assay (CAM), the intersegmental vessel formation in
transgenic TG(fli1:EGFP)y1 zebrafish embryos, the aortic
ring assay, and a battery of in vitro tests [16]. The superior
potency of AD0157 against lymphangiogenesis over angio-
genesis is here supported in two additional pathological
models of angio/lymphangiogenesis, the corneal model
and the ear sponge assay.
From a clinical perspective, it is worth mentioning that
the tyrosine kinase inhibitor sunitinib, available for the
treatment of renal cell carcinoma and metastatic gastro-
intestinal stromal tumors that prove resistant to imatinib
[40–42], has been used in our laboratory in the MDA-
MB-231/Luc+ xenograft and in the mouse cornea
models [17, 18]. Long-term treatment with sunitinib at a
therapeutic dose of 40 mg/kg for 30 days resulted in a
drastic inhibition of primary tumor growth, metastasis for-
mation, and corneal lymphangiogenesis [17, 18]. In both
in vivo approaches, sunitinib was used at 40 mg/kg/day,
while treatments with 3 mg/kg/day AD0157 have shown
similar inhibitory effects in the same models. These obser-
vations reflect that AD0157 is a potent compound and
might be of benefit in the treatment of cancer by
suppressing lymphangiogenesis and LN metastasis. In
addition, this study also highlights the absence of toxicity
in mice during AD0157 treatment, a fact that can help in
the challenge of predicting toxicity in patients based on
preclinical models. All together demonstrate the interest
of considering this compound for future clinical
investigations.
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Finally, and perhaps most importantly, this timely
study provides an example of how primary tumors are
tightly connected with their local microenvironment and
sheds light on the important role played by the lymph-
atic vasculature in cancer progression. Therefore, using
multifunctional compounds such as AD0157, displaying
anti-lymphangiogenic, anti-angiogenic, and anti-tumoral
properties, is a very promising strategy to counteract
cancer progression and metastatic dissemination.
Conclusions
Here, we assign uncovered and potent in vivo, ex vivo,
and in vitro anti-lymphangiogenic functions to AD0157.
This drug through its dual VEGFR-3 and VEGFR-2
cascades inhibition and its apoptotic effect blocks
lymphangiogenesis and prevents LN and distant metas-
tases in a breast cancer model. Our results demonstrate
the interest of considering this compound for future
clinical investigations. The efficacy of AD0157 in other
tumor cell types and mouse models will be explored in
future approaches. Hopefully, this study can also serve
as a precedent for applying similar therapeutic strategies
in lymphatic metastases chemoprevention.
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Additional file 1: Figure S1. Chemical structure of AD0157. (PS 139 kb)
Additional file 2: Figure S2. AD0157 reduces LYVE-1 mRNA expression
in mammary tumors and in draining LNs. Analyses of LYVE-1 expression
by qRT-PCR, normalized to GADPH expression, in mammary MDA-MB-
231/Luc+ tumors and LNs resected from control and AD0157-treated
mice. Values are expressed as mean ± s.e.m. and Wilcoxon-Mann-Whitney
significance tests were used to compare the differences between control
and AD0157 treatments. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 12).
(PS 296 kb)
Additional file 3: Figure S3. AD0157 inhibits LEC and MDA-MB-231/
Luc+ cell proliferation. Representative curves showing the dose-depen-
dent effect of AD0157 on the in vitro growth of LEC and MDA-MB-231/
Luc+ cells. Cell proliferation is represented as a percentage of untreated
cells. Each point represents the mean of quadruplicates; SD values were
typically lower than 10% of the mean values and are omitted for clarity.
The half-maximal inhibitory concentration (IC50) value was calculated
from dose-response curves as the concentration of compound yielding
50% of control cell survival. It is expressed as means ± s.e.m. of five inde-
pendent experiments. (PS 415 kb)
Additional file 4: Figure S4. Effect of AD0157 on MDA-MB-231/Luc+ cell
migration and apoptosis. (a) Closure of the initial scratched area by MDA-
MB-231/Luc+ cells after 48 h in the absence or presence of different
AD0157 doses. Broken lines in pictures indicate the initial (time 0) wound
edges. Scale bars represent 100 μm. (b) Graph shows the percentage of the
initial cell-free area recovered by tumor cells. (c) Representative pictures
showing the effect of AD0157 on MDA-MB-231/Luc+ cell chromatin
condensation after 14 h of treatment. Scale bars represent 100 μm. (d)
Percentages of control and AD0157-treated tumor cells with condensed
chromatin (total cells were counted by using bright field). (e) Percentages of
subG1, G1, and S/G2/M MDA-MB-231/Luc+ cell subpopulations analyzed by
flow cytometry after AD0157 treatment. (PS 17413 kb)
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